Supporting Parents of Young Children With Type 1 Diabetes in Closed-Loop System

NCT ID: NCT03354286

Last Updated: 2019-09-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-11-07

Study Completion Date

2019-03-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will examine the impact of a closed-loop insulin delivery system intervention on health and psychological outcomes in families with young children with Type 1 Diabetes (T1D).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 1 Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Developmental & Technological Demands

Provide education on using diabetes technology in various settings and formats in this age group, and increase ability for real-time problem-solving. Identify and troubleshoot barriers to keeping young children in Auto Mode.

Group Type EXPERIMENTAL

Developmental & Technological Demands

Intervention Type BEHAVIORAL

Education and training related to use of CGM in this age group

Distress Reduction

Identify and reduce parent distress symptoms and worries. Provide strategies for obtaining social support.

Group Type EXPERIMENTAL

Distress Reduction

Intervention Type BEHAVIORAL

Education and training on reducing distress

Nutrition, Set Point, & C:I Ratio

Provide education on a variety of properties of food and how they affect blood glucose levels. Optimize the use of carbohydrate to Insulin ratios, insulin duration of action, and use of temporary target glucose set point in the 670G pump and the Quick bolus feature to gain better glycemic control.

Group Type EXPERIMENTAL

Nutrition, Set Point, & C:I Ratio

Intervention Type BEHAVIORAL

Education and training on how to use the HCL system to dose for different kinds of foods to improve glycemic control

Hypoglycemia management

Focus on hypoglycemia management to avoid hyperglycemia, review fear of hypoglycemia

Group Type EXPERIMENTAL

Hypoglycemia management

Intervention Type BEHAVIORAL

Education and training on reducing worries of hypoglycemia

Minimal Intervention

A short communication detailing the percentage of time spent in range and in Auto Mode and if the goals have been met.

Group Type PLACEBO_COMPARATOR

Minimal Intervention

Intervention Type BEHAVIORAL

Minimal intervention to simulate standard care - serves as the control group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Developmental & Technological Demands

Education and training related to use of CGM in this age group

Intervention Type BEHAVIORAL

Distress Reduction

Education and training on reducing distress

Intervention Type BEHAVIORAL

Nutrition, Set Point, & C:I Ratio

Education and training on how to use the HCL system to dose for different kinds of foods to improve glycemic control

Intervention Type BEHAVIORAL

Hypoglycemia management

Education and training on reducing worries of hypoglycemia

Intervention Type BEHAVIORAL

Minimal Intervention

Minimal intervention to simulate standard care - serves as the control group

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Diagnosis of type 1 diabetes according to ADA diagnostic criteria
2. Time since diagnosis of at least six months
3. Age between 2.00 and 6.99 years at enrollment
4. Parental consent to participate in the study
5. Completion of the CEP 302 Trial and in the continuation phase of the Medtronic CEP 302 Trial using the Medtronic MiniMed 670G pump with Enlite3 sensor.

To be eligible for the study, a parent must meet the following criteria:

1. Parent or legal guardian of a child with type 1 diabetes meeting the "child" criteria outlined above.
2. Age of 18.0 years or older.
3. Parent comprehends written English.
4. Parent understands the study protocol and signs the informed consent document.

The presence of any of the following is an exclusion for the study (since enrollment in the CEP 302 Trial):

1. Child has a medical disorder that in the judgment of the investigator will interfere with completion of any aspect of the protocol (e.g., pregnancy, kidney disease, adrenal insufficiency, skin condition that may hinder sensor application).
2. Child has a neurologic disorder that in the judgment of the investigator will affect completion of the protocol
3. Current use of oral glucocorticoids or other medications, which in the judgment of the investigator would be a contraindication to participation in the study
4. Child is unable to completely avoid acetaminophen for duration of study
Minimum Eligible Age

2 Years

Maximum Eligible Age

6 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Colorado, Denver

OTHER

Sponsor Role collaborator

Indiana University

OTHER

Sponsor Role collaborator

Yale University

OTHER

Sponsor Role collaborator

University of South Florida

OTHER

Sponsor Role collaborator

Stanford University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Bruce A. Buckingham

Professor, Department of Pediatrics, Endocrinology and Diabetes Division

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Stanford University School of Medicine

Palo Alto, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

43167

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.